Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.35 |
| ▸ | CPT1A | P50416 | 8/20 | 0.34 |
| ▸ | CPT1B | Q92523 | 8/20 | 0.34 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL226534 | 0.92 | NR1H4 (0.38) | NR1H4CPT1ACPT1B | |
| SCHEMBL227304 | 0.92 | KDR (0.36) | — | |
| SCHEMBL4481482 | 0.91 | SENP1 (0.35) | NR1H4KDM4EMAPTCPT1ACPT1B | |
| SCHEMBL225790 | 0.90 | NR1H4 (0.39) | NR1H4KDM4EMAPTCYP26B1CYP26A1 | |
| SCHEMBL4500469 | 0.90 | LRRK2 (0.35) | MAPT | |
| SCHEMBL4506120 | 0.89 | LRRK2 (0.42) | MAPT | |
| SCHEMBL4504546 | 0.89 | NPC1 (0.42) | NR1H4KDM4EMAPTCYP26B1CPT1A | |
| SCHEMBL4504553 | 0.89 | NPC1 (0.42) | NR1H4KDM4EMAPTCYP26B1CPT1A | |
| SCHEMBL4485266 | 0.88 | NR1H4 (0.45) | NR1H4KDM4EMAPTCYP26B1CPT1A | |
| SCHEMBL4502977 | 0.88 | NPC1 (0.37) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1527046-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004009546-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | NR1H4 544/4885KDM4E 1648/4885MAPT 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.